A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasting Conditions
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is compare the relative bioavailability of Nifedipine ER tablets 60
mg by Abrica Pharmaceuticals LLLP with that of ADALAT® CC Extended Release Tablets 60 mg by
Bayer Pharmaceuticals Corporation, Bayer HealthCare following a single oral dose (1 x 60 mg
tablet) in healthy adult volunteers under non-fasting conditions